Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
The current price of 3XB0.MU is €3.86 EUR — it has increased by +9.04% in the past 24 hours. Watch Xenetic Biosciences stock price performance more closely on the chart.
What is Xenetic Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Xenetic Biosciences stocks are traded under the ticker 3XB0.MU.
When is the next Xenetic Biosciences earnings date?▼
Xenetic Biosciences is going to release the next earnings report on May 07, 2026.
How many employees does Xenetic Biosciences have?▼
As of April 16, 2026, the company has 2 employees.
In which sector is Xenetic Biosciences located?▼
Xenetic Biosciences operates in the Health & Wellness sector.
When did Xenetic Biosciences complete a stock split?▼
Xenetic Biosciences has not had any recent stock splits.
Where is Xenetic Biosciences headquartered?▼
Xenetic Biosciences is headquartered in Framingham, United States.